Apimeds Pharmaceuticals US, Inc. (NYSE American: APUS) announced that its subsidiary, MindWave Innovations Inc., has entered into a 12-month technology services agreement with Singapore-based AQUAE Holdings Pte. Ltd. to deploy MindWave's MindChain infrastructure as the foundation of AQUAEChain, a platform for insured ALCI Credits. The deal positions MindWave as the technical backbone for a system that will manage the issuance, verification, tracking, transfer, and retirement of ALCI Credits, with ongoing technical support provided throughout the term.
Under the agreement, MindWave will receive contracted software development and technology service fees. More significantly, the agreement references an allocation to MindWave equal to 20% of total ALCI Credits issued and outstanding on the AQUAEChain network, calculated quarterly using the MindChain issuance ledger. This equity-like participation in the credit ecosystem could provide MindWave with a recurring revenue stream tied to the growth of AQUAEChain, aligning its incentives with the platform's success. For Apimeds, a clinical-stage biopharmaceutical company focused on non-opioid, biologic-based therapies for pain management, the deal represents a strategic expansion into blockchain-based climate finance and tokenized environmental assets, potentially diversifying its business beyond drug development.
The agreement also signals the commercial validation of MindChain, MindWave's enterprise blockchain infrastructure, which supports four ecosystems: InsurTech through BlockAssure, ClimateTech through AQUAE and the ALCI index, HealthTech through the Apitox development program, and RWA Tech through Nexus Global Partners. By securing AQUAE Holdings as a client, MindWave demonstrates that its infrastructure can be applied to real-world asset tokenization in the climate sector. The AQUAEChain platform aims to measure, verify, and tokenize ecosystem services into institutional-grade assets, a growing area of interest for investors seeking sustainable and impact-oriented opportunities. Following the initial 12-month term, the parties expect to transition to a five-year continuing technology services arrangement, subject to mutual agreement and definitive documentation, which would provide longer-term visibility for MindWave's technology services revenue.
For investors, the announcement highlights Apimeds' ability to leverage blockchain technology across multiple verticals, potentially creating new value streams beyond its core biopharmaceutical focus. The news was distributed by TechMediaWire, a communications platform specializing in technology companies. TechMediaWire is part of the Dynamic Brand Portfolio @ IBN, which offers wire solutions through InvestorWire, editorial syndication to 5,000+ outlets, press release enhancement, social media distribution, and corporate communications solutions. The full press release can be viewed at https://ibn.fm/eZCn1. For more information about Apimeds, visit www.ApimedsUS.com, and for the latest updates relating to APUS, visit the company's newsroom at https://ibn.fm/APUS. TechMediaWire's terms of use and disclaimers are available at https://www.TechMediaWire.com/Disclaimer.
